Clinical trial · Interventional
The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery
Phase I Clinical Trial Evaluating the Safety and Feasibility of Bone Marrow Aspiration From Ribs During Thoracic Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Initial observations suggest challenges in performing bone marrow aspiration in the first few patients enrolled in the study.
Summary
Brief summary (as posted)
This pilot trial is designed to evaluate the feasibility and safety of obtaining bone marrow from costal aspiration during surgery. The investigators hypothese that sufficient bone marrow-derived HSPC's (which represent only 0,1% of the total bone marrow fraction) can be derived by rib bone marrow aspiration for ex vivo single-cell evaluation, optimization of a 3D BMN platform and preclinical ex/in vivo assessment in patient-derived organoids and murine xenograft models.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood, bone marrow and lung tumor tissue collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Costal bone marrow aspiration
- description
- 4 NSCLC patients undergoing surgery from which blood samples, bone marrow aspirate and lung tumor tissue will be collected
- interventionNames
- Procedure: Blood, bone marrow and lung tumor tissue collection
Primary outcomes (1)
- measure
- The Occurrence of Adverse Events Following Costal Bone Marrow Aspiration Classified by Calvien Dindo
- timeFrame
- 7 days following surgery
- description
- All adverse events will be classified by the Clavien Dindo classification. The study will be closed prematurely if 2 patients experience a grade 3 adverse event directly related to the bone marrow aspiration
Secondary outcomes (1)
- measure
- Measurement of the Amount of HPSC's That Can be Obtained From Costal Bone Marrow
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient undergoing thoracic surgery for a confirmed or suspected lung cancer Exclusion Criteria: * Uncertainty of pre-operative diagnosis, exception is per-op frozen section analysis confirming malignity * ASA ≥ 3 * Bleeding disorders
References
Publications (0)
Data not yet available